CONFORM Trial: SmartBrief Update

March 2, 2026

CONFORM Pivotal Trial

In this Edition of the CONFORM SmartBrief

Enrollment Update & New CONFORM Sites
Uploading Imaging
Access the Referral Letters and Form
The Acquisition of Conformal Medical is now Completed

Enrollment Update & News CONFORM Sites

The CONFORM Pivotal Trial has achieved 40% enrollment, driven by strong site engagement throughout February. Thank you to the following top-enrolling sites for their continued commitment and success during the month:

Arrhythmia Research Group
Baystate Medical Center
University of Kansas Medical Center
Cooper University Hospital Camden
Pro Medical Toledo Hospital
Hartford Health St. Vincent's Medical Center
Bellin Health

This month we welcomed one new site to the CONFORM Study and we are so excited to have them as part of this important research.

New Mexico Heart Institute

Stay up to date on how your site is doing with Enrollment with the CONFORM Trial APP.

CONFORM App

TEE/TTE Sonographer Worksheet

Please ensure that all imaging is uploaded in a timely manner following each study visit. In addition, be sure to include the Echo worksheet corresponding to the correct visit with your submission. Timely and complete uploads are essential to avoid data queries and ensure efficient review.

If you have any questions, please feel free to reach out to your CONFORM Site Manager.

Download Worksheet Here

CONFORM Trial Referral Letters & Form

Download the crafted referral letter and form to help your site to inform referring partners that your hospital/center is enrolling patients the CONFORM Pivotal Trial.

Use the link below to access these files on the RC Portal. You will find these files under the "Startup Documents" section of the site. Remember to access the site use the password AcuFORM2025!

View Here

Acquisition of Conformal Medical is Now Complete

Conformal Medical will continue to operate as a wholly owned subsidiary of Gore within its Medical business. Importantly, our mission and priorities remain unchanged. We are fully focused on the ongoing CONFORM Pivotal Trial and will continue to actively support CONFORM clinical sites with enrollment and trial-related needs. Thank you to all our sites for your support and efforts as we work towards completing the trial.

View Press Release

Have suggestions or questions about this newsletter?

Drop us a note at info@conformalmedical.com.

CAUTION: Investigational Device. Limited by federal (or United States) law to investigational use. Outside the United States, the device is intended exclusively for clinical investigation. Not approved for commercial use.

conformalmedical.com | contact us

DISCLAIMER: The information contained in this email (including any file attachments transmitted with it) is for the sole use of the intended recipient(s) and may contain confidential and privileged information. Any unauthorised review, use, alteration, disclosure, copying or distribution is prohibited. If you have received this email in error, please notify the sender by return email and destroy all copies of the original message. Any confidentiality or privilege is not waived or lost by any mistaken delivery of this email.